BioCentury
ARTICLE | Clinical News

Vital falls on discontinuation of ELAD system

September 12, 2018 3:34 PM UTC

Vital Therapies Inc. (NASDAQ:VTL) lost $5.85 (93%) to $0.45 on Wednesday after the company said it will discontinue development of its ELAD system and explore strategic options. The move comes after newly released data showed that the ELAD system missed the primary and secondary endpoints in the open-label Phase III VTL-308 trial to treat alcohol-induced liver decompensation. ELAD is a human liver cell-based extracorporeal liver assist device.

In VTL-308, ELAD plus standard of care (SOC) showed no significant differences on the primary endpoint of overall survival (OS) through at least day 91 or the secondary endpoint of the proportion of survivors at day 91 vs. SOC alone. Based on the data, Vital said it does not believe the ELAD system can be approved in the U.S. or EU without additional clinical trials...

BCIQ Company Profiles

Vital Therapies Inc.